proTAME (Synonyms: Pro-N-4-tosyl-L-arginine methyl ester) |
Catalog No.GC44730
One-Click Copy Product Info
|
proTAME es un inhibidor de APC/C (Anaphase Promoting Complex/Cyclosome) permeable a las células
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1362911-19-0
Sample solution is provided at 25 µL, 10mM.
proTAME es un inhibidor de APC/C (Anaphase Promoting Complex/Cyclosome) permeable a las células[1]. proTAME se convierte en TAME (Tosyl-L-Arginine Methyl Ester) por esterasas intracelulares, y TAME inhibe especificamente la actividad de APC/C, lo que induce así la detención del ciclo celular en la metafase y, posteriormente, conduce a la muerte celular [2]. proTAME se usa comúnmente en la investigación sobre la regulación del ciclo celular y los estudios relacionados con el cáncer [3][4].
In vitro, el tratamiento proTAME (5, 10, 20, 50 o 100μM; 3h) muestra una detención de metafase dependiente de la dosis en ovocitos de mamíferos y mebriones de escición temperatura, y la detención de la metafase inducida por este medicamento no requiere actividad de punto de control de ensamblaje del huso (SAC) [5]. El tratamiento de las células OVCAR-3 con proTAME(5, 10, 20, 50 o 100μM; 6h) inhibe el crecimiento de las células con un IC50 de 12.5μM[6]. El tratamiento de las líneas celulares de MCL y DLBCL con proTAME (3, 6 y 12µM) durante 24h indujo una metafase prolongada, lo que resultó en la acumulación del sustrato APC/C-Cdc20 ciclina B1, inactivación/degradación de Bcl-2 y Bcl-xL y apoptosis dependiente de caspasa[7].
References:
[1] Zeng, X., Sigoillot, F., Gaur, S., Choi, S., Pfaff, K. L., Oh, D. C., Hathaway, N., Dimova, N., Cuny, G. D., & King, R. W. (2010). Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer cell, 18(4), 382–395.
[2] Zeng, X., & King, R. W. (2012). An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination. Nature chemical biology, 8(4), 383–392.
[3] Lara-Gonzalez, P., & Taylor, S. S. (2012). Cohesion fatigue explains why pharmacological inhibition of the APC/C induces a spindle checkpoint-dependent mitotic arrest. PloS one, 7(11), e49041.
[4] Mayah, A., Arenas, R. B., Bastida, A., & Bolanos-Garcia, V. M. (2025). The Use of APC/C Antagonists to Promote Mitotic Catastrophe in Cancer Cells. Methods in molecular biology (Clifton, N.J.), 2874, 207–213.
[5] Radonova, L., Svobodova, T., Skultety, M., Mrkva, O., Libichova, L., Stein, P., & Anger, M. (2019). ProTAME Arrest in Mammalian Oocytes and Embryos Does Not Require Spindle Assembly Checkpoint Activity. International journal of molecular sciences, 20(18), 4537.
[6] Raab, M., Sanhaji, M., Zhou, S., Rödel, F., El-Balat, A., Becker, S., & Strebhardt, K. (2019). Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia (New York, N.Y.), 21(4), 363–375.
[7] Maes, A., Maes, K., De Raeve, H., De Smedt, E., Vlummens, P., Szablewski, V., Devin, J., Faict, S., De Veirman, K., Menu, E., Offner, F., Spaargaren, M., Moreaux, J., Vanderkerken, K., Van Valckenborgh, E., & De Bruyne, E. (2019). The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British journal of cancer, 120(12), 1137–1146.
| Experimentos celulares [1]: | |
Líneas celulares | Líneas celulares MCL (Jeko-1, Mino y Rec-1) y ABC–DLBCL (U2932 y RI-1) |
Método de preparación | Todas las líneas celulares MCL (Jeko-1, Mino y Rec-1) y ABC–DLBCL (U2932 y RI-1) se mantuvieron en el medio RPMI-1640 suplementado con 10% de suero de ternero fetal (FCS) y 2mM de glutamina. Las células se cultivaron a 37°C en una atmósfera de CO2 humidificada al 5% y se trataron durante 24 horas con proTAME (3, 6 y 12µM). El efecto sobre la viabilidad se determinó utilizando un ensayo CellTiter-Glo y los efectos en los sustratos de los coactivadores APC/C Cdc20 y Cdh1 se investigaron mediante transferencia occidental. |
Condiciones de reacción | 3, 6 y 12μM; 24h |
Áreas de aplicación | proTAME indujo una metafase prolongada, lo que resultó en la acumulación del sustrato APC/C-Cdc20 ciclina B1, inactivación/degradación de Bcl-2 y Bcl-xL y apoptosis dependiente de caspase. |
References: | |
| Cas No. | 1362911-19-0 | SDF | |
| Sinónimos | Pro-N-4-tosyl-L-arginine methyl ester | ||
| Canonical SMILES | CC1=CC=C(S(N[C@H](C(OC)=O)CCC/N=C(NC(OCOC(CC2=CC=CC=C2)=O)=O)/NC(OCOC(CC3=CC=CC=C3)=O)=O)(=O)=O)C=C1 | ||
| Formula | C34H38N4O12S | M.Wt | 726.8 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3759 mL | 6.8795 mL | 13.7589 mL |
| 5 mM | 275.2 μL | 1.3759 mL | 2.7518 mL |
| 10 mM | 137.6 μL | 687.9 μL | 1.3759 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: Viscous paste
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)